重要！科创板第五套标准恢复执行后首家获得受理！

Core Viewpoint - Zhuhai Tainuo Maibo Pharmaceutical Co., Ltd. has received acceptance for its IPO on the Sci-Tech Innovation Board, marking the first company to be accepted under the resumed fifth listing standard since June 18, 2023, which supports unprofitable enterprises in various advanced technology sectors [2][4]. Group 1: Company Overview - The company was established in December 2015 and transformed into a joint-stock company in June 2023, with a registered capital of approximately 391.46 million yuan and a total of 767 employees as of March 2025 [7]. - The company focuses on innovative biopharmaceuticals aimed at global markets, particularly in blood product alternatives, with a commitment to creating clinical value through differentiated innovation [8]. Group 2: Main Business - The core product, Staitouta Monoclonal Antibody Injection (brand name: Xintimuo®), was approved for sale in China in February 2025 and is the world's first tetanus monoclonal antibody drug, recognized as a breakthrough therapy by the China CDE and included in the FDA's Fast Track program [8]. - Another key product, TNM001, is a potential long-acting monoclonal antibody for RSV prevention in infants, currently undergoing Phase III clinical trials [8]. Group 3: Shareholding Structure - The company has no controlling shareholder, with actual control held by Huaxin Liao and Zheng Weihong, who collectively control 33.10% of the company's shares [9]. Group 4: Financial Performance - The company reported revenues of 4.34 million yuan in 2022, 0 yuan in 2023, and projected revenues of 15.06 million yuan in 2024, with net losses of 394.34 million yuan, 467.69 million yuan, and 530.40 million yuan for the respective years [10]. - As of March 31, 2025, the company's asset-liability ratio was 56.48%, with a significant increase in R&D investment as a percentage of revenue, reaching 79331.93% in the first quarter of 2025 [11][12]. Group 5: IPO Fundraising and Investment Projects - The company plans to raise 1.5 billion yuan through its IPO, with 340 million yuan allocated for working capital and the remainder for two key projects: new drug development and the expansion of antibody production facilities [14].